B. Clmnh_manteau, B. J. Pdf, C. R. Salles-g, and . Balter-c, Le lymphome du manteau. http:/www.leucemie-espoir.org Tumor necrosis factor ? release is a major biological event associated with rituximab treatment, The Hematology Journal, vol.2, pp.378-384, 2001.

B. J. and A. A. Dighiero-g, A new prognostic classification of chronic lymphocytic leukaemia derived from a multivariate survival analysis, Cancer, vol.48, pp.198-206, 1981.

H. J. and L. S. Shaffer-d, Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma ? a randomised phase II trial of the

. Immunochemotherapy-with-fludarabine, and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) imporves response rates and progression-free survival of previously untreated patients with advanced chronic lymphocytic leukemia (abstract), Blood, vol.112, p.325, 2008.

H. N. and J. E. Stein-h, A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group classification of non-Hodgkin's lymphoma, Blood, vol.84, pp.1361-1392, 1994.

H. N. and J. E. Stein-h, World Health Organization Classification of neoplastic disease of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, J Clin Oncol, vol.17, pp.3835-3849, 1997.

M. R. Imrie-k and . P. Solal-celigny, Commission de la transparence, Mabthera, avis. http://www.has-sante Phase III study of R-CVP compared with cyclophosphamide, vincristine and prednisone alone in patients with previously untreated advanced follicular lymphoma, HAS J Clin Oncol, vol.26, 2008.

M. R. Ding-l and . Veis-d, Developmental regulation of the bcl-2 protein and susceptibility to cell death in B lymphocytes, EMBOJ, vol.13, pp.683-691, 1994.

M. S. Bowman-w and A. M. , Results of treatment of advanced-stage Burkitt's lymphoma and B-cell stage (SIg+) acute lymphoblastic leukaemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine, J Clin Oncol, vol.4, pp.1732-1739, 1986.

O. , B. S. Kantarjian-h, and T. D. , Rituximab dose-escalation rial in chronic lymphocytic leukaemia, J Clin Oncol, vol.19, pp.2165-2170, 2001.

R. J. Fayard-l and . A. Rodriguez-m, High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine, J Clin Oncol, vol.23, pp.7013-7023, 2005.

S. G. Foussard-c and N. M. , Rituximab added to aIFN+CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: first analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients, Blood, vol.104, p.160, 2004.

S. G. Mounier-n and G. S. , Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA- GOELAMS FL2000 study, Blood, vol.112, pp.4824-4831, 2008.

S. G. and S. J. Feugier-p, Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy, J Clin Oncol, vol.28, 2010.

S. G. Catalano-j and . Feugier-p, Rituximab maintenance for 2 years significantly improves outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy : results of the PRIMA study

S. H. Klein-s and R. U. , Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia, Blood, vol.100, pp.3115-3120, 2002.

S. I. Palomba-c and . Kulangara-k, Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells, Cancer Res, vol.63, pp.534-540, 2003.

S. R. Pagano-a, S. E. , and A. , Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura, Blood, vol.98, pp.952-957, 2001.

W. U. Jensen-m, . Manzke-o, and . Schulz-h, Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody

Y. A. Tsukamoto-n and U. H. , Durable remission induced by rituximab-containing chemotherapy in a patient with primary refractory Burkitt's lymphoma, Ann Hematol, vol.83, pp.120-123, 2004.

Y. R. Longo-d and . Gladstein-e, The treatment of indolent lymphomas: watchful waiting versus aggressive combined modality treatment, Semin Hematol, vol.25, pp.11-16, 1998.

Z. M. Nobili-b and R. U. , Rituximab for the treatment of refractory autoimmune hemolytic anemia in children, Blood, vol.101, pp.3857-3861, 2003.

Z. X. Hu-w and Q. , The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implication for therapy, The Oncologist, vol.13, pp.954-966, 2008.

. Une-récidive-de-la-maladie, Pcq maladie réfractaire (3) ni récidive ni réfractaire, en suivi de l'induction (4) Comme premier traitement de la maladie(5) Raison non disponible / NSP En traitement d'entretien Première dose de rituximab administrée

R. Utilisé-le-patient-reçoit-le-rituximab, ) en monothérapie (2) de la chimiothérapie en concomitance Dose de rituximab : [ ] (1) Dose 375 mg